

LUNG-MAP

A lung cancer precision medicine trial

VOLUME 27 | SPRING 2025

NEWSLETTER

WWW.LUNG-MAP.ORG

S1800E Non-Match Is Open

Patients with advanced non-small cell lung cancer whose genomic profile does not match a Lung-MAP biomarker sub-study now have **a non-match option**.

S1800E activated on April 28th! It is enrolling non-matched patients whose disease progressed after platinum-based chemotherapy and anti-PD-1 or anti-PD-L1 therapy.

This phase II/III sub-study asks whether adding immunotherapy during treatment with second- or third-line docetaxel and ramucirumab can reverse acquired resistance to immune checkpoint inhibitors and lead to improved survival outcomes.

S1800E patients are randomized to standard of care docetaxel and ramucirumab with or without cemiplimab, an anti-PD-1 monoclonal antibody.

S1800E study chair is Saiama N. Waqar, MD, MSCI, of Washington University School of Medicine. Dr. Waqar is also vice chair of the Lung-MAP trial.

*"It's been beautiful for me,
and it's improved my quality of life immensely,
and I'm very, very thankful for it."*



Austin A., a patient with advanced non-small cell lung cancer at the White River Junction VA Medical Center in Vermont, speaking about the Lung-MAP clinical trial. His disease has remained stable during two years of treatment on S1800D, Lung-MAP's most recent non-match sub-study.

LEARN
MORE:

[S1800E CTSU page](#)

[S1800E site initiation training](#)

LEARN MORE AT WWW.LUNG-MAP.ORG



S1900K Revised Eligibility Includes Treatment-Naïve Patients

A March [revision to sub-study S1900K](#) expands eligibility to include patients who have not yet undergone treatment for their non-small cell lung cancer.

S1900K is a randomized phase II study of tepotinib with or without ramucirumab in patients with MET exon 14 skipping positive, Stage IV or recurrent NSCLC.

Under the revised protocol, patients who have received any number of lines of therapy for Stage IV or recurrent NSCLC – including *zero* lines – may now be eligible for the sub-study.

Since this S1900K revision posted in March, four additional patients have been enrolled, bringing total accrual to seven.

When EA5182 Patients Have Disease Progression, Think S1900G

Has your site enrolled to ECOG-ACRIN's EA5182? When patients on EA5182 experience disease progression, they may become eligible for Lung-MAP's S1900G sub-study.

- EA5182 is enrolling treatment-naïve patients with metastatic EGFR-mutant non-small cell lung cancer and randomizing them to osimertinib with or without bevacizumab. About 20 percent of patients on osimertinib go on to develop resistance via MET amplification.
- S1900G is enrolling patients whose EGFR-mutant NSCLC has become MET-amplified on osimertinib treatment.

At disease progression, EA5182 patients can be screened for Lung-MAP. Those whose tumors have acquired MET amplification may be eligible for assignment to sub-study S1900G.

The EA5182 trial has accrued about 240 patients thus far. For some, S1900G may be a fitting next stop on their treatment journey.

LEARN
MORE:

[S1900G CTSU page](#)

[Webinar: "An Overview of EGFR-Mutant Lung Cancer: How S1900G & EA5182 fit into the treatment paradigm"](#)

Webinar on S1900J & S1900K Is Now Online

A recording of a March 31st [educational webinar on sub-studies S1900J and S1900K](#) is available in the CLASS learning management system, linked under "Protocol Related Documents" from the CTSU.org protocol pages for S1900J, S1900K, and LUNGMAP.

The ASCO Post

ABOUT • NEWS • MEETINGS • TOPICS • VIDEOS • PODCASTS • SUBSCRIBE

Lung-MAP 3.0: Simplifying the Process to Meet Patients' Needs

By KAREN L. RECKAMP, MD, MS
February 25, 2025

[Get Permission](#)



Karen L. Reckamp, MD, MS

The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non-small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol initiated by the National Cancer Institute (NCI), the NCI's National Clinical Trials Network led by SWOG (formerly known as the Southwest Oncology Group) Cancer Research Network, the U.S. Food and Drug Administration, the Foundation for the National Institutes of Health (NIH), Friends of Cancer Research, leading academic researchers and institutions, patient advocacy groups, and industry!

This Lung-MAP design allows multiple targeted treatments and immunotherapies to be tested simultaneously and independently of the other substudies, permitting the efficient addition of novel substudies, as new promising treatment options emerge. This umbrella trial focuses on precision medicine, and the structure enables patients' tumors to be genetically profiled, matching them to specific substudies targeting molecular alterations or biomarkers identified in their cancer while still allowing therapeutic nonmatch substudy options for patients without genomic alterations that match any of the available Lung-MAP biomarker-driven substudies. The trial is an adaptive clinical trial platform designed to improve treatment options for patients with advanced NSCLC.


Incorporating Next-Generation Sequencing Into Standard of Care

The Lung-MAP trial was launched in 2014 for squamous NSCLC to establish an infrastructure for biomarker screening and for the rapid regulatory intent evaluation of targeted therapies at a time when standard-of-care genomic testing for this type of lung

Lung-MAP 3.0 in ASCO Post

Lung-MAP chair Karen Reckamp, MD, penned an editorial in the February 25th *ASCO Post*: "[Lung-MAP 3.0: Simplifying the Process to Meet Patients' Needs.](#)"

In the piece, Reckamp says "Lung-MAP 3.0 was introduced to expand genomic screening through a variety of commercial and academic next-generation sequencing platforms to align with current testing patterns and remove barriers to study accrual." She also discusses how the trial addresses cancer care inequities and improves patient outcomes.



Lung-MAP Advocacy Webinar: May 14th

Advocating, Accelerating, and Amplifying Lung Cancer Discovery
Wednesday, May 14th, 1 – 2 pm ET
Hosted by the Lung-MAP Accrual Enhancement Committee

This webinar will include brief trial updates and a talk on Lung-MAP opportunities and challenges from a community clinician's perspective, given by a community oncologist who has been one of Lung-MAP's highest accruers.

The centerpiece of the event will be a panel discussion with leaders of three of the largest lung cancer advocacy organizations.



Lung-MAP Advocacy Webinar: Advocating, Accelerating, and Amplifying Lung Cancer Discovery



LUNG-MAP

Wednesday, May 14th
1:00PM – 2:00PM ET
Virtual Webinar

[Register today](#)

Learn more and register to attend at swog.org/lung-map-webinar.

TOP-ACCRUING SITES TO LUNGMAP*

| | | |
|--|-----------------|-----|
| UPMC Hillman Cancer Center | Pittsburgh, PA | 154 |
| Edwards Comprehensive Cancer Center | Huntington, WV | 86 |
| UNM Comprehensive Cancer Center | Albuquerque, NM | 77 |
| Wilmot Cancer Institute Univ of Rochester | Rochester, NY | 60 |
| Palo Alto Medical Foundation – Sunnyvale | Sunnyvale, CA | 60 |
| Harold Alfond Center for Cancer Care | Augusta, ME | 53 |
| Missouri Baptist Medical Center | St. Louis, MO | 52 |
| Cleveland Clinic Mercy Medical Center | Canton, OH | 49 |
| VA Connecticut Healthcare System – West Haven | West Haven, CT | 40 |
| Eastern Maine Medical Center Cancer Care | Brewer, ME | 40 |
| St. Mary's Medical Center | Huntington, WV | 40 |
| Dartmouth Hitchcock Med Ctr/Dartmouth Cancer Ctr | Lebanon, NH | 39 |
| Baystate Medical Center | Springfield, MA | 38 |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | 37 |
| AnMed Health Cancer Center | Anderson, SC | 37 |

* As of May 10, 2025



**AS OF MAY 10, 2025,
THE NEW LUNGMAP
SCREENING PROTOCOL
HAS LOGGED:**

3,628

screening registrations

1,888

sub-study assignments

503

sub-study registrations

CONTACT US

Request Review of New NGS Test
LungmapNGS@swog.org

General Medical Questions
LUNGMAP@swog.org

Protocol & Regulatory Questions
jbeeler@swog.org

Eligibility & Data Submission Questions
LUNGMAPQuestion@crab.org

Central Monitoring Questions
centralmonitorquestion@crab.org

Quality Assurance Auditing Questions
qamail@swog.org

Funding Questions
funding@swog.org

S1800E Study Chairs
S1800EMedicalQuery@swog.org

S1900G Study Chairs
S1900GMedicalQuery@swog.org

S1900J Study Chairs
S1900JMedicalQuery@swog.org

S1900K Study Chairs
S1900KMedicalQuery@swog.org

The latest list of acceptable NGS tests for Lung-MAP screening is at swog.org/lung-map-resources.
Click on "LUNGMAP NGS Testing Reference Page."